• The diagnosis of antiphospholipid syndrome (APS) requires both characteristic clinical features and persistently abnormal laboratory tests.
Introduction
Antiphospholipid syndrome (APS) is an acquired autoimmune disorder associated with vascular thrombotic events, pregnancy failure and an array of additional clinical manifestations involving other organs, such as the heart, skin and central nervous system. With effective management many of the complications of the condition can be avoided; the importance of early recognition and diagnosis needs to be emphasised.
The disease can be a discrete entity (primary APS) or it can occur in association with other autoimmune disease, usually systemic lupus erythematosus (SLE). Patients with primary APS have similar clinical profiles to those with APS plus SLE, although certain features such as heart valve disease, haemolytic anaemia, low C4 levels and neutropenia are more common in the latter.
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Prevalence
The syndrome occurs most commonly in young to middle-aged adults. Women are more frequently affected (female:male ratio of 5:1). There is no racial predominance for primary APS, although a higher prevalence of SLE occurs in the black and Hispanic populations.
Clinical features
Diagnostic criteria for the classification of definite APS were agreed by an international panel in 1999 and updated in 2006 (Box 1).
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Thrombosis is the most common presenting feature of APS. 4 It can occur in the venous, arterial or small-vessel circulations. It can involve vascular beds infrequently affected by other prothrombotic states and is independent of atherosclerotic vascular disease.
Venous thrombosis
Antiphospholipid antibodies (aPL) are found in about 2% of patients presenting with acute venous thromboembolism. The venous thrombosis often occurs in unusual sites such as the cerebral, retinal, splanchnic or axillary veins; APS accounts for up to 70% of such presentations. Venous thromboembolism, especially deep venous thrombosis of the legs, occurs in 30-50% of patients with APS during an average follow-up of less than 6 years.
5 Following a first episode the risk of future venous thrombosis increases significantly.
Arterial thrombosis
The most common site of arterial thrombosis is the central nervous system, with cerebrovascular events and transient ischaemic attacks accounting for 50% of arterial events in APS. Myocardial infarction accounts for about 20% and other vascular beds that can be involved include those of the lungs, retina, gut, spleen and extremities. In many cases the event is otherwise unexplained, with no identifiable risk factors for arterial disease, such as smoking, diabetes or hypertension.
Obstetric complications
Some women with APS have no problems at all in pregnancy; however, pregnancy complications, in addition to maternal thrombosis, can occur at any stage. These include recurrent first-trimester miscarriages, late fetal loss, fetal growth restriction, pre-eclampsia and placental abruption.
Pregnancy loss
Of women with recurrent pregnancy loss, defined as three or more first-trimester miscarriages, 10-20% have detectable aPL. 6 These women have a potential 90% risk of further fetal loss if left untreated. 7 The diagnostic criteria for APS suggest that evaluation should begin after the third consecutive early miscarriage, defined by less than Box 1 Summary of the revised classification criteria for APS Antiphospholipid syndrome can be diagnosed if at least one of the clinical and one of the laboratory criteria are met (although not if there is Ͻ12 weeks or Ͼ5 years between the positive antiphospholipid antibody test and the clinical manifestation).
Clinical criteria
• Vascular thrombosis: one or more clinical episodes of arterial, venous or microvascular thrombosis occurring in any tissue or organ (superficial venous thrombosis is not included)
• 10 weeks of gestation (Box 1). However, in practice, evaluation after two early miscarriages is often initiated at the discretion of the physician.
Late complications of aPL in pregnancy
These relate to placental insufficiency caused by aPL. Gestational hypertension/pre-eclampsia occurs in 30-50% of untreated women with known APS, but falls to 10% with effective management. By contrast, there is no increase in aPL incidence in general obstetric patients presenting with pre-eclampsia. 8 HELLP syndrome (haemolysis, elevated liver enzymes and low platelets) may occur, usually associated with pre-eclampsia/eclampsia; this seems to occur earlier than in women without APS, often in the second trimester.
Other clinical manifestations
In addition to thrombosis and obstetric morbidity, there are additional clinical manifestations that are not included in the official definition of APS (Box 2).
Catastrophic APS
This term defines a severe, accelerated form of APS resulting in multi-organ failure from widespread thromboses, which are usually microvascular rather than large-vessel occlusions. The syndrome is of acute onset, defined by the involvement of at least three different organ systems over a period of days to weeks. The pathogenesis appears to be dependent on a multi-hit phenomenon. Triggers such as infection or surgery exacerbate an already procoagulable state.
Postpartum syndrome This is a rare syndrome characterised by pleuropulmonary disease, fevers and cardiac manifestations. 9 The mechanism is unknown, although extensive immunoglobulin IgG, IgM, IgA and C3 deposition in the myocardium has been reported.
Antiphospholipid antibodies
It was originally thought that aPL were directed against negatively charged phospholipids but it is now clear that they target plasma proteins with affinity for these phospholipids. The main antigens involved are ␤ 2 -glycoprotein I (␤ 2 GPI) (also known as apolipoprotein H) and prothrombin, although many more antigenic targets have been described. Implicated antibodies include lupus anticoagulant, anticardiolipin antibodies (aCL) and anti-␤ 2 GPI. There is concordance between them but they are not identical and some lupus anticoagulants react with phospholipids other than cardiolipin and proteins other than ␤ 2 GPI, whereas some aCL and anti-␤ 2 GPI have no lupus anticoagulant activity. Antibodies to the ␤ 2 GPI are persistent and associated with thrombotic complications, whereas those independent of ␤ 2 GPI tend to be present only transiently, associated with infectious diseases or drugs.
Pathophysiology and aetiology
Evidence suggests that multiple mechanisms are responsible for the varying clinical manifestations. Notably, recurrence of complications often follows a similar pattern of disease and recurrent thrombosis usually occurs in the same vascular field, although this is not always the rule.
Procoagulant effects ␤ 2 GPI antibodies disrupt normal coagulation mechanisms in several ways: direct cellular effects caused by bound ␤ 2 GPI-antibody complexes, activating platelets, endothelial cells and monocytes, hence inducing tissue factor expression; interference with haemostatic factors; resistance to activated protein C; and reduction in fibrinolysis.
Obstetric morbidity
The pathophysiological mechanisms underlying obstetric morbidity also appear to be multiple, involving either thrombotic or non-thrombotic phenotypes in the placenta. It is likely, also, that genetic and environmental factors affecting the maternal-fetal interface influence the potential pathogenicity of these antibodies.
Early histological studies demonstrated decidual vasculopathy and placental thrombosis. Displacement of annexin V from trophoblasts contributes to a procoagulant state through acceleration of coagulation reactions. In addition, a mouse model 10 demonstrated activation of complement, causing inflammation-mediated placental injury leading to fetal loss or growth restriction. In this model, heparin prevented pregnancy loss by blocking activation of complement, rather than primarily via an anticoagulant effect.
More recently, direct trophoblastic damage by aPL, independent of mechanisms involving thrombosis and complement activation, has been demonstrated. Interaction of aPL with ␤ 2 GPI, exposed during trophoblast syncytium formation, has been shown to cause inhibition of trophoblast invasiveness. This mechanism has been hypothesised to contribute to early pregnancy loss.
Laboratory evaluation
Limitations of laboratory testing include lack of laboratory standardisation for aPL and the heterogeneous nature of the antibodies, resulting in low specificity of the assays. Antiphospholipid antibodies are found in 3-5% in those without thrombosis or obstetric morbidity. They are often transient and associated with infection or drugs.
The clinical importance of these aPL is uncertain.
To satisfy APS laboratory classification criteria, persistently positive antibody tests in at least one of the three assays (aCL, lupus anticoagulant or ␤ 2 GPI antibody) for at least 12 weeks is required. Testing should occur away from the time of the acute event.
2,3 There is no indication for screening for aPL in asymptomatic women prior to interventions such as in vitro fertilisation.
Lupus anticoagulant
This is the most relevant assay in relation to vascular events and obstetric morbidity. These antibodies are detected by their ability to prolong phospholipid-dependent coagulation reactions, not corrected by mixing patient and normal plasmas. As aPL showing lupus anticoagulant activity are heterogeneous, it is recommended that at least two methods are performed: activated partial thromboplastin time (APTT) and a direct anti-Xa assay such as the dilute Russell viper venom assay (dRVVT). It should be confirmed, using a phospholipid neutralisation procedure, that the anticoagulant is directed against protein bound to negatively charged phospholipids.
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Anticardiolipin antibodies
These are measured by enzyme-linked immunosorbent assay, although, again, concordance among laboratories is poor and it is difficult to distinguish between significant antibodies associated with ␤ 2 GPI from those bound to other plasma proteins or directly bound to cardiolipin. The correlation between aCL titre and thrombotic risk is well established, with the IgG subtype having stronger association than IgM or IgA. 12 The revised classification criteria for APS uses an IgG aCL threshold of 40 iu. Low levels of aCL, although statistically abnormal, may not be associated with a significant risk of thrombosis and in a systematic review of the literature, Galli et al. 13 observed no correlation with venous thrombosis and only a weak correlation with arterial thrombosis.
Anti-␤ 2 -glycoprotein I antibodies
These are now included in the revised criteria for the diagnosis of APS (Box 1).
2 They show better correlation with thrombosis than aCL but there is a high false-positive rate as there are non-pathogenic antibodies that bind ␤ 2 GPI.
Management of APS in pregnancy
General issues
The aims of management of APS in pregnancy are threefold:
1. To maximise the chance of successful fetal outcome. 2. To prevent thrombosis and other clinical manifestations of APS in the mother. 3. To ensure good counselling and planning for future pregnancies.
Wherever possible, women should be seen in a prepregnancy counselling setting, so that a full review can be carried out and their general health optimised.
A detailed past medical and obstetric history should be taken and the circumstances of any past thrombotic event (provoked or spontaneous, arterial or venous) assessed. Asessment should also be made of any associated conditions, such as SLE, and evidence of any organ damage. Other risk factors contributing to thrombotic risk or pregnancy morbidity such as obesity and maternal age must be taken into account in the overall assessment and will contribute to making an appropriate individualised treatment plan.
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There is debate regarding what constitutes the most appropriate pharmacological management for pregnant women with APS: guidelines often leave exact treatment to the discretion of the physician involved. The heterogeneity of the condition complicates this decision further. The standard anticoagulant for prevention and treatment of venous thromboembolism in pregnancy is heparin, usually low molecular weight. With respect to the pathophysiology of APS, it is the logical drug of choice, as it has both anticomplement and anti-inflammatory actions in addition to its anticoagulant effect. Two randomised studies 15 performed in the late 1990s concluded that a combination of aspirin plus heparin is the optimal treatment. A Cochrane review 16 of small studies concluded that this regimen may reduce pregnancy loss by 54%. Subsequently, combination treatment became standard practice. However, a recent large randomised trial 17 contests this, finding no advantage in dual treatment in the study and no advantage when these data are analysed together with previously published studies. A meta-analysis published in 2010 which analysed five studies came to the opposite conclusion. 18 Hence, this remains a controversial area. It may be that the conflicting results are due to heterogeneity in the cases and that further stratification is necessary in treatment according to clinical phenotype, as suggested by Bramham et al. 19 A summary of management of women with APS or aPL is given in Table 1 and discussed in the following sections.
Management of an acute episode of thrombosis in pregnant women with APS
The immediate management of thrombosis is the same in those with or without APS. This standard treatment consists of low molecular weight heparin in a therapeutic dosage. The various treatment schedules for different low molecular weight heparins are summarised in Table 2 .
Management of women with aPL and a previous thrombotic event
It is likely that these women will be on long-term anticoagulation, although this depends on the circumstances of the thrombotic event. If there was clearly a temporary provoking factor, they may have had a limited duration of anticoagulation.
• In those women on long-term anticoagulation, a change from warfarin should be made once a positive pregnancy test is obtained. It is important to emphasise the necessity of an early pregnancy test, to ensure a change to heparin before 6 weeks of gestation and, therefore, to minimise the risk of warfarin embryopathy. The dosage of heparin should be at intermediate or therapeutic levels, depending on assessment of overall risk.
• In those women not on anticoagulation, a high prophylactic or intermediate dosage should be commenced early in the first trimester, on confirmation of a viable pregnancy.
• Aspirin at a low dosage (75 mg) should also be started.
• Women then require regular, frequent review throughout the pregnancy: fetal biometry to assess fetal growth should be performed at monthly intervals from 20 weeks of gestation. Studies show that analysis of uterine artery Doppler at 18-22 weeks predicts poor pregnancy outcome.
20 Subsequent regular monitoring of umbilical artery Doppler is recommended.
• Postnatally, the woman may be re-established on warfarin or continue on heparin for at least 6 weeks.
Management of women with aPL and multiple previous venous events, or venous plus arterial events
This group of women will be on long-term warfarin, possibly at higher range international normalised ratio, 3, 4 and are at very high risk during pregnancy. In this group, prepregnancy counselling is particularly important, so that the extent of risk can be clarified on an individual basis, prepregnancy health optimised, and this risk and a clear plan conveyed to the woman and documented. Heparin in therapeutic dosages should be substituted for warfarin, together with low dose aspirin and regular fetal growth assessment as above.
Occasionally, there are women in an 'ultra-high' risk group, where it may be appropriate to consider warfarin usage from the second trimester, or even all trimesters. These women include those who continue to develop new thrombotic events despite anticoagulation. The risks of warfarin to the fetus must be explained: in the first trimester this includes a 1-2% risk of teratogenicity and, later, the ongoing risk of fetal loss, haemorrhage and subtle neurological changes.
Management of women with aPL and pregnancy morbidity
In the randomised trial by Rai et al., 15 low dose aspirin plus heparin increased the live birth rate to 71%, compared with 42% with low dose aspirin alone. Two meta-analyses concurred, showing reduction in pregnancy losses by 54%; other studies are conflicting, one showing a good success rate with aspirin alone, and others demonstrating no superiority of aspirin to placebo. There is no place for steroids in the management of these women since this is associated with maternal morbidity and premature delivery.
Generally, prophylactic dosages of low molecular weight heparin and low dose aspirin are recommended in women with recurrent pregnancy loss and other pregnancy morbidities.
In addition, fetal monitoring with umbilical artery Doppler ultrasound every 3-4 weeks from 24-26 weeks provides important information on fetal wellbeing. Huong et al. 20 analysed the predictive value of Doppler ultrasound examination for late pregnancy outcome, together with clinical examination and laboratory tests in Table 2 Approximate prophylaxis and treatment schedules for different low molecular weight heparins women with SLE and/or APS. A notched uterine artery at the second trimester was the only predictor for adverse pregnancy outcome from a multivariate analysis of 100 cases.
Occasionally, other treatments are used if the above management fails, including increasing the dosage of heparin, intravenous immunoglobulin infusions and, in rare cases, plasma exchange. These have been successfully used in anecdotal cases.
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Management of women with aPL but no clinical features These women do not fulfil the criteria for the diagnosis of APS. Management of women who have isolated aPL, with no prior pregnancy loss or thromboembolic phenomena, do not generally merit antenatal pharmacological treatment, although low dose aspirin is often used.
The best predictor of maternal and fetal outcome in APS pregnancies is the previous obstetric history.
Where there is a previously normal obstetric history despite aPL, any future pregnancy is likely to have a low risk of complications and women should be reassured of this.
Management of women with APS as part of SLE
Women with SLE may have a flare-up of symptoms during pregnancy and require steroids. Hydroxychloroquine and azathioprine are regularly used in SLE: they are safe in pregnancy and so should be continued as necessary.
Management of women with APS and thrombocytopenia
Many patients with APS have thrombocytopenia (platelets Ͻ100 ϫ 10 9 /l). The pathogenic antibodies are directed towards platelet membrane glycoproteins and are distinct from aPL. Patients should be managed in the same way as for immune thrombocytopenia. Where there has been previous thrombosis, the fine balance between bleeding and thrombotic risk must be carefully managed and a platelet count Ͼ50 ϫ 10 9 /l should be maintained to allow safe pharmacological thromboprophylaxis.
Prepregnancy planning
This should be offered to all women with APS, taking all risk factors into consideration. It may be necessary to recommend deferring pregnancy in order to improve general health and reduce risk, such as the need for weight loss, following an acute thrombotic event or treatment of active SLE. There may be circumstances where pregnancy should be actively discouraged; for example, if pulmonary hypertension is present the risk of maternal death is estimated at Ͼ35%.
A clear plan for pregnancy management should be developed as outlined in Box 3. 
